PROX1-AS1: A Drug Target / Disease Biomarker (G100505832)

Target Name: PROX1-AS1

NCBI ID: G100505832

PROX1-AS1

Other Name(s): PROX1 antisense RNA 1

PROX1-AS1: A Drug Target / Disease Biomarker

Prox1-AS1, also known as AS1-Prox1, is a protein that is expressed in the endoplasmic reticulum (ER) and is involved in the regulation of axon growth factor (AGF) signaling. AGF is a cytokine that has been shown to play a role in the development and maintenance of cancer, and is often used as a therapeutic target in cancer treatment.

Recent studies have identified Prox1-AS1 as a potential drug target for cancer treatment. By inhibiting the activity of Prox1-AS1, researchers have found that they can reduce the growth of cancer cells and inhibit the formation of new blood vessels that these cells use to promote their growth.

One of the reasons why Prox1-AS1 is considered a promising drug target is that it is highly conserved across different species, which means that it is likely to be effective in treating cancer in a variety of organisms. Additionally, Prox1-AS1 is expressed in most tissues and cells, which makes it a potential target for cancer treatment that can be used in combination with other therapies.

In addition to its potential as a cancer treatment, Prox1-AS1 is also being investigated as a biomarker for the diagnosis and prognosis of cancer. By measuring the levels of Prox1-AS1 in cancer cells and patient samples, researchers have found that lower levels of Prox1-AS1 are associated with poorer prognosis in cancer patients.

Overall, Prox1-AS1 is a protein that is being studied as a potential drug target for cancer treatment and as a biomarker for the diagnosis and prognosis of cancer. Further research is needed to fully understand its role in these processes and to develop effective treatments for cancer.

Protein Name: PROX1 Antisense RNA 1

The "PROX1-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PROX1-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets